---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-178615"
form_type: "8-K"
ticker: null
cik: "0001169245"
company_name: "PhaseBio Pharmaceuticals Inc"
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T20:57:25.525086+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PhaseBio Chapter 11 plan confirmed; creditors ~1.6% recovery, equity zero

## Summary
- Bankruptcy Court confirmed liquidation plan on June 26, 2024; all assets to Liquidation Trust.
- General unsecured creditors expected ~1.6% recovery; equity holders expected no recovery.
- All ~50.2M shares of common stock to be canceled on Effective Date of the Plan.
- Company reported assets ~$2.7M and liabilities ~$41.9M in May 2024 operating report.
- Plan includes releases for officers, directors, and certain service providers from claims.

## SEC filing metadata
- accession: 0001193125-24-178615
- form_type: 8-K
- cik: 0001169245
- company_name: PhaseBio Pharmaceuticals Inc
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1169245/000119312524178615/0001193125-24-178615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1169245/000119312524178615/d854608d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-178615
- JSON: https://secwatch.observer/filing/0001193125-24-178615.json
- Plain text: https://secwatch.observer/filing/0001193125-24-178615.txt

## Key facts
- Distress & Bankruptcy
  PhaseBio Pharmaceuticals Inc entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2022-10-23).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court for the District of Delaware
  - Petition: 2022-10-23
  source text: On October 23, 2022, PhaseBio Pharmaceuticals, Inc. (the "Company" or the "Debtor") filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case (the "Chapter 11 Case") for the Company (Case No. 22-10995).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1169245/000119312524178615/0001193125-24-178615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.